PETRI DISH PERSPECTIVES

Manead Khin
  • 0,0 (0)
  • БИОНАУКИ

Burma | ChicagoScientist 🥼🧪🔬Covering biotech, pharma, and healthcare companies shaping the world 🧬🏥🌎 Stream new episodes every THURSDAY! https://linktr.ee/maneadkhin #biotech #pharma #healthcare #podcast #petridishperspectives

  1. -3 ДН.

    Episode 45: BioMarin

    Send a text Most biotech companies chase massive markets. But BioMarin Pharmaceutical built its entire strategy around something very different: ultra-rare genetic diseases affecting only small patient populations around the world. In this episode of Petri Dish Perspectives: Biotech Unleashed, we break down how BioMarin became one of the most influential rare-disease biotech companies in the industry. We explore the company’s founding vision, the scientific pathways behind its major therapies, and how its team translated academic discoveries into real treatments for patients with conditions that once had no options. We also dive into the discovery and development stories behind BioMarin’s key drugs, from enzyme replacement therapies that defined the early rare-disease model to newer innovations targeting genetic signaling pathways and gene therapy. Along the way, we examine the strategy that allowed BioMarin to build a sustainable biotech business in markets most pharma companies once ignored. If you want to understand how rare disease innovation works and why this niche has become one of the most important sectors in biotech, this episode is for you. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday! https://linktr.ee/maneadkhin #Biotech #RareDisease #BioMarin #DrugDevelopment #GeneticDiseases #Pharma #Biotechnology #LifeSciences #HealthcareInnovation #GeneTherapy #BiotechPodcast #PetriDishPerspectives Support the show © 2026 Petri Dish Perspectives LLC. All rights reserved.

    24 мин.

  2. 1 МАР.

    February 2026: Biotech & Pharma NEWS Roundup

    Send a text Welcome to your essential overview of the global biotech and pharmaceutical landscape for February 2026! This month was dominated by by three massive themes: The Great IPO Thaw, the "AI Factory" Era, and Regulatory Hardball. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes! https://linktr.ee/maneadkhin #PetriDishPerspectives #BiotechNews #PharmaNews Support the show © 2026 Petri Dish Perspectives LLC. All rights reserved.

    11 мин.

  3. 26 ФЕВР.

    Episode 44: BioNTech

    Send a text Before the world knew the power of mRNA vaccines, BioNTech was a relatively quiet biotech company focused on one ambitious goal: curing cancer through the immune system. Then the COVID-19 pandemic changed everything. In this episode of Petri Dish Perspectives: Biotech Unleashed, we explore how BioNTech evolved from an academic vision into one of the most important biotechnology companies of the 21st century. We break down the scientific bet on mRNA, the early years building a platform many investors didn’t fully understand, and the pivotal partnership with Pfizer that helped deliver one of the fastest vaccine developments in history. But the story doesn’t stop with COVID. We also examine the criticisms, the people behind the company’s rise, and the next frontier BioNTech is chasing — personalized cancer vaccines and the future of programmable medicine. If you want to understand how a biotech platform can reshape global health and what comes after a once-in-a-generation breakthrough, this episode is for you. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday! https://linktr.ee/maneadkhin #Biotech #BioNTech #mRNA #Biotechnology #Pharma #DrugDevelopment #COVID19 #Vaccines #BiotechPodcast #LifeSciences #HealthcareInnovation #PetriDishPerspectives Support the show © 2026 Petri Dish Perspectives LLC. All rights reserved.

    25 мин.

  4. 19 ФЕВР.

    Episode 43: ARCH Venture Partners

    Send a text In this episode of Petri Dish Perspectives, we unpack the strategy and scientific conviction behind ARCH Venture Partners, the venture firm that has quietly helped build some of the most transformative companies in modern biotechnology. From early bets on platform technologies like gene editing and mRNA to backing next-generation leaders such as Juno, Editas Medicine, Beam Therapeutics, and rising metabolic players like Metsera, ARCH has consistently invested at the frontier, long before the science was commercially proven. We explore how ARCH’s concentrated, high-conviction model differs from traditional venture capital, why it prioritizes platform biology over single assets, and how patience, scientific depth, and risk tolerance have allowed the firm to shape entire therapeutic categories. If you want to understand the invisible capital forces behind CRISPR, mRNA, cell therapy, and the obesity drug boom, this episode is for you. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday! https://linktr.ee/maneadkhin #Biotech #VentureCapital #ARCHVenturePartners #Biopharma #DrugDevelopment #CRISPR #mRNA #SyntheticBiology #HealthcareInnovation #StartupEcosystem #LifeSciences #MetabolicHealth #GeneEditing #PetriDishPerspectives Support the show © 2026 Petri Dish Perspectives LLC. All rights reserved.

    24 мин.

  5. 12 ФЕВР.

    Episode 42: Otsuka

    Send a text In this episode of Petri Dish Perspectives, we explore the fascinating evolution of Otsuka Holdings, a company that defies traditional pharmaceutical stereotypes. From its origins in Japan as a chemical and nutrition-focused business to becoming a global biopharma innovator, Otsuka has built its reputation by targeting complex and often misunderstood disease areas such as psychiatric disorders, kidney disease, and digital medicine. We unpack the scientific and business journey behind blockbuster therapies like Abilify, examine how Otsuka balanced pharmaceuticals with nutrition and consumer health, and dive into the company’s unique culture of long-term thinking and unconventional innovation. We also explore how Otsuka expanded globally, navigated patent cliffs, embraced partnerships, and positioned itself for the future through digital therapeutics and precision medicine. If you’re interested in how companies succeed by thinking differently and what Otsuka teaches us about patience, diversification, and patient-centered innovation; this is an episode you won’t want to miss. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday! https://linktr.ee/maneadkhin #Biotech #Pharma #Otsuka #DrugDevelopment #HealthcareInnovation #Biopharma #LifeSciences #PharmaceuticalIndustry #MentalHealthInnovation #DigitalTherapeutics #GlobalPharma #PrecisionMedicine #PetriDishPerspectives #BiotechPodcast Support the show © 2026 Petri Dish Perspectives LLC. All rights reserved.

    23 мин.

  6. 5 ФЕВР.

    Episode 41: Gene Therapies

    Send a text What if medicine could fix disease at its source… by rewriting the genetic code itself? In this episode of Petri Dish Perspectives, we dive into the incredible story of gene therapy, one of the most ambitious and transformative frontiers in modern medicine. From early scientific discoveries about DNA and viral delivery systems, to heartbreaking clinical setbacks that nearly shut the field down, and finally to today’s life-changing treatments for rare diseases, cancer, and genetic disorders, gene therapy represents decades of persistence, innovation, and scientific courage. We explore the researchers who refused to give up, the breakthroughs that revived the field, and the biotech companies leading today’s gene therapy revolution, including pioneers developing CRISPR editing, viral vector platforms, and personalized cellular therapies. We also break down why gene therapy is reshaping the pharmaceutical industry and what the future may hold for curing previously untreatable diseases. If you love biotech, cutting-edge science, and the stories behind medical breakthroughs, this is an episode you don’t want to miss. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday! https://linktr.ee/maneadkhin #GeneTherapy #Biotech #Genetics #CRISPR #CellTherapy #RareDisease #CancerResearch #Biopharma #MedicalInnovation #PrecisionMedicine #SciencePodcast #LifeSciences #DrugDevelopment #FutureOfMedicine #PetriDishPerspectives Support the show © 2026 Petri Dish Perspectives LLC. All rights reserved.

    26 мин.

  7. 1 ФЕВР.

    January 2026: Biotech & Pharma NEWS Roundup

    Send a text Welcome to your essential overview of the global biotech and pharmaceutical landscape for January 2026! This month was dominated by a surge in Eli Lilly's deals, partnerships, etc.  🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes! https://linktr.ee/maneadkhin #PetriDishPerspectives #BiotechNews #PharmaNews Support the show © 2026 Petri Dish Perspectives LLC. All rights reserved.

    11 мин.

  8. 29 ЯНВ.

    Episode 40: Eisai

    Send a text What does it take to spend decades chasing one of medicine’s hardest problems while the rest of the industry walks away? In this episode, we explore the remarkable story of Eisai, the Japanese pharmaceutical company that built its global identity around Alzheimer’s disease. From its founding during World War II and early commitment to ethical medicine, to the blockbuster success of Aricept, and finally the long, controversial road to Leqembi, Eisai’s journey is one of persistence, philosophy, and scientific conviction. We break down how Eisai partnered with Biogen, why leadership under Haruo Naito stayed the course when others exited neuroscience, and how a Japan-based company became a global force in CNS drug development. Along the way, we examine Eisai’s approach to risk, regulation, M&A, and what its future looks like beyond Alzheimer’s. This is a story about long-term thinking in a short-term industry and what happens when belief outlasts doubt. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday! https://linktr.ee/maneadkhin  #Eisai #Biotech #Pharma #Alzheimers #Neuroscience #DrugDevelopment #Biogen #HealthcareInnovation #PharmaHistory #LifeSciences #BiotechPodcast #ScienceAndBusiness #PetriDishPerspectives Support the show © 2026 Petri Dish Perspectives LLC. All rights reserved.

    23 мин.
См. все (49)

Об этом подкасте

Burma | ChicagoScientist 🥼🧪🔬Covering biotech, pharma, and healthcare companies shaping the world 🧬🏥🌎 Stream new episodes every THURSDAY! https://linktr.ee/maneadkhin #biotech #pharma #healthcare #podcast #petridishperspectives

Информация

  • Автор
    Manead Khin
  • Годы выхода
    2025 - 2026
  • Выпуски
    49
  • Ограничения
    С ненормативной лексикой
  • Авторские права
    © 2026 PETRI DISH PERSPECTIVES
  • Сайт подкаста
    PETRI DISH PERSPECTIVES